［1］ ABU-TINEH M,KASSEM N,ABDULLA MA,et al.Outcome of pregnancy in the era of PEGylated interferon-α2a in females with chronic myeloid leukemia:An experience from Qatar［J］.Case Reports in Oncology,2020,13(1):291-294.
［2］ KURZROCKR,GUTTERMAN JU,TALPAZ M.The molecular genetics of philadelphia chromosome-positive leukemias［J］.The New England Journal of Medicine,1988,319(15):990-998.
［3］ ASSI R,KANTARJIAN H,KEATING M,et al.Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor:a single-center experience［J］.Leukemia & Lymphoma,2021,62(4):909-917.
［4］ HEHLMANN R.The new ELN recommendations for treating CML［J］.Journal of Clinical Medicine,2020,9(11):3671.
［5］ BASCIANI S,DE LUCA G,DOLCI S,et al.Platelet-derived growth factor receptor beta-subtype regulates proliferation and migration of gonocytes［J］.Endocrinology,2008,149(12):6226-6235.
［6］ SZAKACS Z,HEGYI PJ,FARKAS N,et al.Pregnancy outcomes of women whom spouse fathered children after tyrosine kinase inhibitor therapy for chronic myeloid leukemia:A systematic review［J］.PloS One,2020,15(12):e0243045.
［7］ NURMIO M,KALLIO J,TOPPARI J,et al.Adult reproductive functions after early postnatal inhibition by imatinib of the two receptor tyrosine kinases,c-kit and PDGFR,in the rat testis［J］.Reproductive Toxicology,2008,25(4):442-446.
［8］ HEIM C,MINNIEAR K,DANN CT.Imatinib has deleterious effects on differentiating spermatogonia while sparing spermatogonial stem cell self renewal［J］.Reproductive Toxicology,2011,31(4):454-463.
［9］ LAW AD,DONG HWAN KIM D,LIPTON JH.Pregnancy:part of life in chronic myelogenous leukemia［J］.Leukemia & Lymphoma,2017,58(2):280-287.
［10］DOLK H,NICHOLS R.Evaluation of the impact of chernobyl on the prevalence of congenital anomalies in 16 regions of Europe.EUROCAT Working Group［J］.International Journal of Epidemiology,1999,28(5):941-948.
［11］窦雪琳,秦亚溱,石红霞,等.慢性髓性白血病患者的生育和疾病结局［J］.中华血液学杂志，2019，40(12):980-985.
DOU XL,QIN YZ,SHI HX,et al.Fertility and disease outcomes in patients with chronic myeloid leukemia［J］.The Chinese Journal of Hematology，2019，40(12):980-985.
［12］BERNARD V,BOUILLY J,KRAMER P,et al.The tyrosine kinase inhibitor sunitinib affects ovulation but not ovarian reserve in mouse:A preclinical study［J］.PloS One,2016,11(4):e0152872.
［13］AHMADI N,SAMAEE SM,YOKEL RA,et al.Imatinib mesylate effects on zebrafish reproductive success:Gonadal development,gamete quality,fertility,embryo-larvae viability and development,and related genes［J］.Toxicology and Applied Pharmacology,2019,379:114645.
［14］OZKAVUKCU S,KUSCU N,ADIGUZEL D,et al.Deleterious reproductive effects of nilotinib in mouse model［J］.Reproduction:The Official Journal of the Society for the Study of Fertility,2021,161(3):295-306.
［15］HOCHHAUS A,BACCARANI M,SILVER RT,et al.European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia［J］.Leukemia,2020,34(4):966-984.
［16］MILOJKOVICD,APPERLEY JF.How I treat leukemia during pregnancy［J］.Blood,2014,123(7):974-984.
［17］ABRUZZESE E,TRAWINSKA MM,PERROTTI AP,et al.Tyrosine kinase inhibitors and pregnancy［J］.Mediterranean Journal of Hematology and Infectious Diseases,2014,6(1):e2014028.
［18］RUSSELL MA,CARPENTER MW,AKHTAR MS,et al.Imatinib mesylate and metabolite concentrations in maternal blood,umbilical cord blood,placenta and breast milk［J］.Journal of Perinatology,2007,27(4):241-243.
［19］BHANDARI A,ROLEN K,SHAH BK.Management of chronic myelogenous leukemia in Pregnancy［J］.Anticancer Research,2015,35(1):1-11.
［20］CHELYSHEVA E,TURKINA A.Risks and challenges of CML management during pregnancy:Looking for a balanced decision［J］.European Journal of Haematology,2019,102(4):378-379.
［21］LASICA M,WILLCOX A,BURBURY K,et al.The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia［J］.Leukemia & Lymphoma,2019,60(7):1796-1802.
［22］ETIENNE G,GUILHOT J,REA D,et al.Long-term follow-up of the french stop imatinib (STIM1) study in patients with chronic myeloid leukemia［J］.Journal of Clinical Oncology,2017,35(3):298-305.
［23］ROSS DM,PAGANI IS,SHANMUGANATHAN N,et al.Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells［J］.Leukemia,2018,32(12):2572-2579.
［24］SAUSSELE S,RICHTER J,GUILHOT J,et al.Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI):a prespecified interim analysis of a prospective,multicentre,non-randomised,trial［J］.The Lancet Oncology,2018,19(6):747-757.
［25］ABRUZZESE E,TRAWINSKA MM,DE FABRITIIS P,et al.Management of pregnant chronic myeloid leukemia patients［J］.Expert Review of Hematology,2016,9(8):781-791.
［26］CAMPIOTTI L,SUTER MB,GUASTI L,et al.Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level:A systematic review and a meta-analysis［J］.European Journal of Cancer,2017,77:48-56.
［27］CASAZZA RL,LAZEAR HM,MINER JJ.Protective and pathogenic effects of interferon signaling during pregnancy［J］.Viral Immunology,2020,33(1):3-11.
［28］ROTH MS,FOON KA.Alpha interferon in the treatment of hematologic malignancies［J］.The American Journal of Medicine,1986,81(5):871-882.
［29］SAKAI K,UEDA A,HASEGAWA M,et al.Efficacy and safety of interferon alpha for essential thrombocythemia during pregnancy:two cases and a literature review［J］.International Journal of Hematology,2018,108(2):203-207.
［30］STALEY EM,SIMMONS SC,FELDMAN AZ,et al.Management of chronic myeloid leukemia in the setting of pregnancy:when is leukocytapheresis appropriate? A case report and review of the literature［J］.Transfusion,2018,58(2):456-460.
［31］KRAKOFF IH,BROWN NC,REICHARD P.Inhibition of ribonucleoside diphosphate reductase by hydroxyurea［J］.Cancer Research,1968,28(8):1559-1565.
［32］WOO GH,BAK EJ,NAKAYAMA H,et al.Molecular mechanisms of hydroxyurea(HU)-induced apoptosis in the mouse fetal brain［J］.Neurotoxicology and Teratology,2006,28(1):125-134.
［33］GWER SO,ONYANGO KO.Prevalence and incidence of congenital anomalies amongst babies born to women with sickle cell disease and exposed to hydroxyurea during pregnancy:a systematic review protocol［J］.JBI Database of Systematic Reviews and Implementation Reports,2018,16(5):1135-1140.
［34］GALERA P,HAYNES S,SULMASY P,et al.Physiological measurements corroborate symptomatic improvement after therapeutic leukapheresis in a pregnant woman with chronic myelogenous leukemia［J］.Journal of Clinical Apheresis,2016,31(4):393-397.
［35］SCHWARTZ J,PADMANABHAN A,AQUI N,et al.Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American society for apheresis:The seventh special issue［J］.Journal of Clinical Apheresis,2016,31(3):149-162.
［36］PALANI R,MILOJKOVIC D,APPERLEY JF.Managing pregnancy in chronic myeloid leukaemia［J］.Annals of Hematology,2015,94 Suppl 2:S167-176.
［37］APPERLEY J.CML in pregnancy and childhood［J］.Best Practice & Research.Clinical Haematology,2009,22(3):455-474.
［38］ABRUZZESE E,MAURO M,APPERLEY J,et al.Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia:opinion,evidence,and recommendations［J］.Therapeutic Advances in Hematology,2020,11:2040620720966120.
［39］ALI S,JONES GL,CULLIGAN DJ,et al.Guidelines for the diagnosis and management of acute myeloid leukaemia in pregnancy［J］.British Journal of Haematology,2015,170(4):487-495.
［40］RODRíGUEZ-GALLEGO I,LEON-LARIOS F,CORRALES-GUTIERREZ I,et al.Impact and effectiveness of group strategies for supporting breastfeeding after birth:A systematic review［J］.International Journal of Environmental Research and Public Health,2021,18(5):2550.
［41］SACHS HC.The transfer of drugs and therapeutics into human breast milk:an update on selected topics［J］.Pediatrics,2013,132(3):e796-809.